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Abstract 
The CRISPR/Cas9 system is a precisely targeted bacterial defense system, used to control 
invading viruses. This technology has many potential applications including genetic changes in 
somatic and germ cells and the creation of knockout animals. Compared to other genome editing 
techniques such as zinc-finger nucleases and transcription activator-like effector nucleases 
(TALENS), the CRISPR/Cas9 system is much easier and more efficient. Most importantly, the 
multifunctional capacity of this technology allows simultaneous editing of several genes. The 
CRISPR/Cas9 system also potentially has the ability to prevent and treat human diseases. The 
present article addresses some key points related to the use of the CRISPR/Cas9 system as a 
powerful tool in cardiovascular research and as a new strategy for the treatment of cardiovascular 
disease (CVD).  
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The drive towards personalized medicine has gained momentum among researchers in recent 
years. Scientists have succeeded in the in vitro treatment of cancer, congenital malformations, 
bacterial and viral infections, and the production of genetically modified food with the aid of the 
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) system. The accumulation 
of individual characteristics, gleaned from genomics, proteomics and phenotypic parameters has 
not only directed research towards health and disease, but has also led to alterations in and 
optimization of available methods for calculating risk likelihood, diagnostic tests and therapeutic 
strategies (1).  
In 1987, a group in Japan described the CRISPR system in Escherichia coli as 29-nucleotide 
repeats separated by 32 nucleotides as spacers, which protects bacteria and archaea against 
bacteriophage and plasmid invasion. These defense systems rely on a small RNA that detects 
specific sequences and extinguishes external nucleic acids (2). Indeed, the CRISPR system is a 
kind of safety system that lies in the genetic code of our cells. The CRISPR regions are 
nucleotide repeats separated by unique spacers. The structure of these DNA sequences is 
complementary for the genome of various viruses (bacteriophages) that attack bacteria. Later 
came the discovery of Cas proteins possessing the ability to cleave DNA strands into two. The 
Cas proteins form a complex with RNA obtained after transcribing the spacer sequence; they 
search inside the cell to find the DNA fragments of the invasive viruses with their 
complementary sequences in order to eliminate them using the Cas enzyme (3). In principle, 
viral DNA fragments, by being stored in the chromosome and creating memory for the bacterial 
immune system, are preparing the virus for subsequent attacks. The human immune system 
works similarly, but in a more advanced manner. To date, six different CRISPR systems have 
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been discovered, initially three types from I to III, followed by IV to VI. The characteristics of 
each system, such as the mechanism of transmission, expression and change to identify and 
create a gap in the target DNA, are different according to their individual mechanisms during the 
process of immunogenicity. In general, researchers only use the bacterial type II CRISPR/CAS9 
system, which includes guide RNA (gRNA), as the best option for generating changes in the 
genome as well as genetic engineering (4). 
The type II CRISPR/Cas9 system exploits a single Cas9 nuclease. This enzyme acts in 
coordination with two gRNAs of crRNA (CRISPR RNA) and tracRNA (transacting CRISPR 
RNA). To optimize the usage of this system, researchers apply a joining loop to generate a dual-
trac RNA called a single guide RNA (sgRNA), which, together with Cas9 endonuclease, creates 
a specific gap in the target sequence. A conserved 2-5 base pair DNA sequence called 
protospacer adjacent motif (PAM) reading in the opposite direction to the RNA-DNA hybrid is 
essential for identifying the target DNA sequence by Cas9.  
Upon detecting the target sequence, a double-strand cleavage occurs by the two Cas9 domains. 
These domains consist of HNH (to cleave crRNA complementary strand) and RuvC-like (to 
cleave the template strand). By using this mechanism, the nuclease designed with sgRNA is 
capable of creating a genomic DNA cleavage in a specific site, resulting in an accurate and 
definitive change in the genome. Modification of a small number of gRNA sequence bases, 
which are complementary to the target sequence, together with the Cas9 protein, allows new 
targets to be easily defined. The capacity to induce multiplex double-strand cleavages in a 
genome due to the expression of different types of RNA in the system is among other capabilities 
of the Cas9 protein (5). Following the DNA double-strand cleavage, the damage is corrected by 
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one or two major repair paths, Homology Directed Repair (HDR) and NHEJ (Non-Homologous 
End Joining). 
The NHEJ is an error-prone method in which double-strand cleavage is repaired via short 
deletions and insertions; therefore, researchers often use this system to induce mutation and 
deactivation of the gene. In contrast, HDR is a precise method as the repair mechanism is based 
on the use of a template strand; hence, this route is mainly applied to delete or duplicate precisely 
the fragments of the target genome, or to precisely insert an external gene into a predetermined 
site in the genome (6). To sum up, pros and cons of these methods can be stated as follows: 
NHEJ-break ends can be ligated without a homologous template, whereas HDR-breaks requires 
a template to guide repair. NHEJ is a very efficient repair mechanism that is most active in the 
cell. It is also susceptible to frequent mutation errors due to nucleotide insertions and deletions 
(indels). HDR is considered the dominant mechanism for precise DSB repair, but suffers from 
low efficiency as it requires higher sequence similarity between the severed and intact donor 
strands of DNA. There are fewer errors or chances of mutations if the DNA template used during 
repair is identical to the original undamaged DNA sequence To make changes in a gene using 
CRISPR , the population of transfected cells will contain a mixture of NHEJ-repaired and HDR-
repaired alleles. HDR-edited DNA is much more attractive to guarantee controlled modifications 
(7-8) 
 Ex vivo and in vivo studies in animal models: 
Today, the application of the CRISPR/Cas9 method has expanded into a variety of areas, 
including agriculture, husbandry, disease patterns and targeted therapies. This section 
emphasizes the therapeutic aspects for diseases with a genetic basis, especially monogenic 
disorders (9). In gene therapy, a gene with pathologic properties can be modified by both ex vivo 
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and in vivo approaches. In the ex vivo approach, the targeted cell population is removed from the 
patient's body, and the designed nucleases are used to induce the desired changes and then 
returned to the patient by grafting. Avoiding issues such as transplant rejection and immune 
responses are important benefits of this method. Using in vivo gene therapy, the genomic 
modifying factors, such as programmatic nucleases and patterns, are put directly into the patient 
(10). 
  
Gene therapy for genetic diseases: 
Gene therapy refers to manipulating sequences and stimulating deletion mutations to provide 
protective function in the host. The optimal diseases to target with gene therapy are monogenic 
disorders. The acquisition of only one copy of an impaired gene can be offset by one normal 
gene and thereby prevent disease development. Polygenic disorders involve multiple variations 
in the genome simultaneously, creating a major challenge in the treatment of these diseases.  
Targeted alterations of genes, both in somatic cells and in germ cell lines, have been reported in 
animal models. The treatment of a particular disease clearly requires knowledge of its genetic 
basis. Molecular scissors can be used to create multiple changes in the genome and repress 
disease development. Access to genetic information on complex diseases has enabled genome 
editing technology (GET) to offer opportunity for treatment of complex multifactorial illnesses, 
such as cardiovascular disease (11). 
In a recent study, a mutation in the MYBPC3 gene was targeted using the CRISPR-Cas genomic 
editing technique to correct this mutation in a human embryo with hypertrophic cardiomyopathy, 
a condition that would eventually cause heart failure. Interestingly, the paternal mutated gene, 
when restricted by CRISPR-Cas9, is more efficiently replaced by the maternal gene rather than 
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by synthesized DNA. Human embryonic manipulation was much more efficient (72.2%) than 
that of iPSC stem cells (17.61%-27.9%). This suggests that the human embryo utilizes the DNA 
repair mechanism differently from somatic and stem cells. Using Cas9 protein injection 
prevented any off-target effects (12). 
 
Cardiovascular disease 
Cardiovascular disease (CVD) is the leading cause of mortality globally (13). CVD is widely 
associated with both inherited and non-inherited diseases. While personalized medicine has 
become a goal, and genome sequencing data are increasingly available from patients, the 
experimental and functional studies enabling understanding of how genetic differences are 
involved in promoting disease are lacking. Recent GETs have enabled studies of biological 
function of genes in both cell systems and animal models (14).  
In this review, we highlight the latest technologies for genome editing, describe their use in 
different in vitro and ex vivo systems, and focus on how technological advances in genome 
editing may lead to deeper understanding of, and treatment for, CVD (15).  
 
Therapeutic potential of the CRISPR/Cas9 system for the treatment of CVD 
The CRISPR/Cas9 system can be used for therapeutic purposes, not only by the correction of 
disease-related mutations, but also through introduction of protective mutations and targeting of 
viral genomes (16). Recently, Limpitikul et al. edited a mutation in the Calmodulin 2 (CALM2) 
gene in the iPSC-CM, thereby preventing cardiac arrthymias due to long QT syndrome (LQTS) 
(17). Calmodulin-related diseases (Calmodulinopathies) associated with LQTS occur due to a 
mutation in one of the CALM1, CALM2, and CALM3 genes. In this case, the proband under the 
©2020, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
7 
 
influence of the malignant calmodulinopathic LQTS is located on only one of the six coded 
alleles of calmodulin. Here, a CRISPR intervention strategy (CRISPRi) was used to select only 
the mutated allele. The CRISPRi technology uses the dCas9 protein to regulate gene expression 
at the transcriptional level. The dCas9-sgRNA complex binds to the targeted gene in the coded or 
coding tail, inhibits the polymerization activity of RNA and prevents the onset of transcription or 
elongation (18). With successful inhibition of the mutated allele, the authors have proposed that 
this method can be applied, not only to other calmodulinopathies such as catecholaminergic 
polymorphic ventricular tachycardia (CPVT), but also to a variety of cardiac and non-cardiac 
diseases characterized by transcription of a damaged gene (19). Although attractive as a strategy, 
the efficacy of genomic editing methods for treatment depends upon the development of a 
successful strategy for the CRISPR/Cas9 system in the patients. This can be obtained ex vivo 
using a patient-to-patient strategy via editing and then transplanting back into the patient, or by 
directly delivering the CRISPR / Cas9 system to the desired site in the specific tissue (Fig. 1 (a) 
and 1 (b)) (19). 
The CRISPR/CAS9 system can target many tissues and organs; however, it is difficult to 
effectively limit it to only a particular targeted tissue. The majority of ex vivo studies insert the 
CRISPR/Cas9 components using adeno-associated viral vectors (AAVs), but AAV tissue 
tropism is limited to certain organs (20). 
 
In vitro methods for CRISPR/Cas9 
Although in vitro models, such as modified cell culture, are widely used because they are 
relatively easy to maintain and manage including simplicity, species specificity, convenience 
and automation. It is true that these can not reflect the complexity of the various cells in 
©2020, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
8 
 
physiological processes, but the benefits mentioned above are valuable in that they are still 
exciting to use.(15). One attractive in vitro system is human pluripotent stem cell lines (hPSC 
lines). These patient-derived cells are generated from induced pluripotent stem cells (iPSC), and 
can be reprogrammed and then differentiated into a variety of cells for functional analysis. 
However, comparing iPSC lines from different individuals can be confusing because of differing 
epigenetics and differing capacities to differentiate into the type of desired cell. The creation of 
homogeneous and isogenic cell lines using genome editing to introduce specific changes in the 
field (reprogramming and differentiation) of interest can circumvent this issue, providing a 
more reproducible model of genetic changes. The production of isogenic hPSC lines using Zinc 
Finger Nucleases (ZFNs are engineered DNA binding proteins that can be designed to bind to a 
wide variety of DNA sequences and function by introducing a double stranded break at a 
specified location in the genome)(21), Transcription activator-like effector nuclease (TALEN 
technology leverages artificial restriction enzymes generated by fusing a TAL effector DNA-
binding domain to a DNA cleavage domain) (22) or CRISPR/Cas9 has increased knowledge 
about cardiomyopathy, including Barth syndrome (a mitochondrial dysfunction disorder caused 
by mutations in the tafazzin (TAZ) gene). Gene replacement and genome editing have shown 
that a TAZ mutation is both necessary and sufficient for the manifestation of these phenotypes, 
as sarcomere assembly and abnormalities of myocardial contractility have occurred despite total 
ATP levels of the cell falling within normal limits (23). 
According to published reports, TALENs uses 15 genes in somatic cell cultures or human-
derived stem cells to produce rapid and efficient mutated alleles (24). Other uses are in lipid 
disorders (25), electrophysiological disorders (26), and valvular heart disease (27). Zhang et al. 
reported that CRISPR/CAS9 ablation of individual miRNAs from a miRNA family disclosed 
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their individual efficacies in regulating cardiac differentiation. During differentiation of 
embryonic stem cells, individual miRNAs from the miRNA17 family (composed of 14 miRNAs) 
do not share the same function, even though they have the same seed sequence. The 
CRISPR/CAS9 technology is not only enlightening in terms of individual miRNA function, but 
also adds advanced molecular biology approaches to classical cell biology approaches such as 
gene rescue. Findings indicate that miRNA106a, and to a lesser extent miR17 and 93, can target 
the cardiac suppressor gene Fog2, which specifically suppresses Gata-4 and Coup-TF2. 
However, when each miRNA was individually knocked out, targeting efficacies for Fog2 
differed, resulting in varying degrees of cardiac differentiation (28).  
CRISPR/Cas9 was used to edit DMD mutations by deleting exons via exon skipping. In proof-
of-concept investigations, myoediting was performed in human-derived iPSCs from several 
patients with large deletions, point mutations or duplications within the DMD gene, and to 
efficiently engineer dystrophin protein expression in derivative cardiomyocytes. In 3D 
engineered heart muscle (EHM), myoediting of DMD mutations altered dystrophin expression 
and the corresponding mechanical force of contraction. Correcting only a subset of 
cardiomyocytes (30% to 50%) was adequate to edit the mutant EHM phenotype to levels close to 
normal. The authors concluded that the rejection of conserved RNA splicing acceptor/donor sites 
and the guidance of the splicing machinery to skip mutant or out-of-frame exons through 
myoediting allowed correction of DMD-related cardiac disorders (29).  
Modeling disease using hPSCs was less than optimal because the influence of individual genetic 
variation on cell phenotype can be greater than from the pathogenic mutation; gene editing using 
Cas9/CRISPR solves this issue. A simplified PiggyBac (PB) strategy is a highly efficient 
transposon originally isolated from Trichoplusia ni,(30) like other transposons, has two 
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components, a transposon and a transposase. The precise ‘cut and paste’ transposition 
mechanism makes PB a powerful tool for mutagenesis and transgenic manipulation. PB 
can accommodate relatively large DNA fragments without compromising transposition 
efficiency, exhibits significantly higher transposition efficiency in mammalian cells and 
multiple copies of PB can incorporate into the host genome providing for the possibility of 
multiple simultaneous manipulations of the host genome (31)  ) shortened the hPSC 
correction by up to two weeks and needed only a single round of clonal expansion and 
genotyping rather than two rounds, delivering identical efficiencies when compared to the longer 
conventional process. A successful outcome was achieved across four heart-related sites 
(ADRB2, GRK5, RYR2, and ACTC1) with genomic cleavage and efficacy correction have 
been shown to be 8% -93% and 67% -8% respectively, which include mono and / or 
biallelic events. Differentiation into high-purity cardiomyocytes conserved pluripotency (CMs; 
88%-99%). Using GRK5 isogenic lines as an exemplar, chronic stimulation with the β-
adrenoceptor agonist isoprenaline decreased beat rate in hPSC-CMs expressing GRK5-Q41 but 
not GRK5-L41; this was reversed by the β-blocker propranolol. This footprint-free shortened 
approach will prove useful for mechanistic studies (32).  
Following is an example of CRISPR/Cas9 application in modifying cholesterol levels, to 
better understand this method. In a study conducted by Hai, quantitative trait loci were 
mapped for the concentrations of free cholesterol and esterified cholesterol and the 
esterified/free cholesterol ratio was measured in acetylated bone marrow-derived 
macrophages (BMDMs) loaded by low-density lipoprotein (LDL), derived from an 
AKR×DBA/2 strain intercross.  The prioritization of the studied loci suggested the Soat1 
(sterol O-acyltransferase 1) gene-containing locus on distal chromosome 1, which encodes 
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Acyl-coenzyme A:cholesterol acyltransferase 1 (ACAT1) and causes the esterification of the 
free cholesterol. The deletion of exon 2 was found in the parental AKR strain in Soat1, 
resulting in curtailment of 33 amino acids in the N-terminal end of ACAT1. The deletion of 
Soat1 exon 2 in the AKR strain was replicated by CRISPR/Cas9 gene edition strategy for 
DBA/2 embryonic stem (DBA/2 ES) cells, without change in the remainder of genome when 
leaving. The results showed the differentiation of DBA/2 ES cells and stem cells 
heterozygous/ homozygous for the Soat1 exon 2 deletion into macrophages, which were 
loaded with acetylated LDL. Less free cholesterol and higher esterified cholesterol were 
accumulated in the macrophages derived from DBA/2 ES cell compared to stem cells 
heterozygous/homozygous for the Soat1 exon 2 deletion (33).  
 
In vivo methods for CRISPR/Cas9 
In vivo genome editing requires the correction of various diseases in the primary cells in situ. A 
smaller cas9 protein from Staphylococcus aureus has recently been described that makes it 
possible to release CRISPR/Cas9 using adeno-associated virus vector (34). Proof-of-concept 
studies on preclinical mice have been carried out using genome editing. Using CRISPR/Cas9 by 
NHEJ, faulty exon can be cleaved or repaired and remove the dystrophin gene leading to 
Duchenne muscular dystrophy (DMD), resulting in significant improvement in muscle function 
(35).  
In vivo therapeutic genome editing in the cardiovascular system faces several major barriers, 
however, catastrophic consequences may occur in rare cases, despite improvement in predictor 
algorithms. First, NHEJ correction mechanisms may lead to cellular dysfunction or tumor 
formation. Second, induction of double-strand cleavage of a healthy allele involved in regulating 
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heterozygote mutations may lead to deterioration of the phenotype. Third, cellular correction 
mechanisms depend upon the stage of the cell cycle; while NHEJ can lead to DNA editing 
during G1, S, and G2 phases, normal HR is limited to the late S and G2 phases when sister 
chromatids are present (36). Since most cardiomyocytes in the postnatal heart are post-mitotic, 
new research seeks to apply HR correction to post-mitotic cells. However, NHEJ mediated exon 
skipping may be technically feasible especially for mutations in titin (TTN) and myosin binding 
protein C3 (MYBPC3) (37). Fourth, unlike skeletal muscle satellite cells that have a huge 
regenerative potential, the inherent regenerative capacity of an adult heart is highly limited. 
Therefore, a substantial number of cardiomyocytes must be successfully edited to induce 
improvements in cardiac function.  
These physiological and technical limitations currently present, important challenges for in vivo 
genome editing for the treatment of cardiomyopathies (34). Beside cardiomyocytes, endothelial 
cells and smooth muscle cells might also be useful targets for in vivo genome editing in the 
treatment of CVD. One possible scenario is the correction of validated genomic variants in 
endothelial cells, as noted in genome-related studies (38-39). Different disease-causing or 
disease-modifying factors will likely be discovered due to more readily available whole exome 
and whole genome sequencing. However, not all of these factors are present in genes expressed 
specifically in endothelial or smooth muscle cells, making cell-specific delivery of CRISPR/Cas9 
difficult for clinical applications. In this regard, CRISPR/Cas9 technology shows significant 
improvement over the limitations of conventional procedures (40-41).  
Zebrafish have gained in popularity over mice as a developmental model of heart disease 
because of relative ease of performing genetic analysis. The delivery of adequate oxygen during 
the first week of development is not a limitation in zebrafish as it is in other models, therefore 
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the zebrafish model allows the study of cardiovascular developmental abnormalities that would 
result in fetal death in other organisms. The zebrafish heart has great regeneration potential that 
is not found in other vertebrates such as rodents (42). Several CRISPR/Cas9-based systems for 
genome editing have been reported in zebrafish (43). Recently introduced is a tool to produce a 
gene-specific tissue by injection of gRNA and Cas9 mRNA into a single stage of the embryo 
cell. As previously described in Drosophila, this offers the possibility of controlling the disorder 
of a particular gene in the cardiomyocytes and markedly improves the ability to test loss of 
function in zebrafish, which could be used not only to delineate embryonic heart phenotypes but 
also to model adult heart disease (44).  
The CRISPR/Cas9 system, which is directly applicable to embryos, has become a popular tool 
for research in rodent models. Older methods needed to induce homologous recombination in 
mouse embryonic stem cells, the selection of mutant ESCs through antibiotic resistance, the 
elimination of false antibiotics, and ESC injection into blastocyst-receiving mice (45). In 
contrast, the CRISPR/Cas9-based technology provides the possibility of producing mutated 
mice in only one step, including simultaneous injection into Cas9 mRNA sprouts, different 
sgRNA and DNA donors (46).  
The CRISPR/Cas9 system can be used for in vivo gene editing in somatic cells. Suppression of 
the PCSK9 gene using the CRISPR/Cas9 tool resulted in lowered blood cholesterol levels and 
reduced coronary heart disease (CHD) risk (47). Chadwick et al. reported significantly reduced 
blood lipid levels after in vivo CRISPR-based genome editing in mice where functional 
mutations in Angptl3 encoding a lipoprotein lipase inhibitor were introduced. The treatment in 
wild type and Ldlr-/- mice was effective and had the same effect as Pcsk9 genome editing without 
causing unpredictable mutations (48). Regarding the comparison of CRISPR method with 
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other therapies such as monoclonal antibodies alirocumab and evolocumab, it is important 
to acknowledge that these drugs received approval from the FDA in 2015 and long term 
safety is not yet established. An additional major concern is the high cost of PCSK9 
inhibitors and their effect on healthcare costs as well as health insurance premiums (49). 
 
Conclusion 
Since its identification and development, the CRISPR/Cas9 system has been shown to be a 
powerful tool creation of new cell and animal models for the study of pathophysiological 
mechanisms in a number of diseases. The therapeutic potential of CRISPR/Cas9 for CVD is a 
challenge due to technical and biological barriers, especially the postmitotic nature of 
cardiomyocytes. Cardiac fibroblasts, endothelial cells and smooth muscle cells are the main cell 
targets using this technique. The development of advanced tools is needed to meet the goal of 
routine use of this technique in CVD therapy. 
  













Figure 1. Functional structure of gRNA/Cas9 Complex 
Figure 2. The CRISPR / Cas9 genome editing system has two components: a) endonuclease 
b) RNA short sequence guide. The last 20 bp of the gRNA are used as an Identifier of DNA 
sequencing and lead Endonuclease Cas9 to the target sequence. Then, Cas9 cuts DNA in the 
3-4 bp upstream of the PAM sequence. Subsequently, DSB will be restored by NHEJ or 
HDR. 
Figure 3. Diagram of the process that occurs within the CRISPR-Cas9 gene editing complex. 
In this figure in vivo and ex vivo gene therapy is explained diagrammatically. In this mode of 
gene therapy, genes are transferred to the cells grown in culture, and the transformed cells are 
selected, multiplied and then introduced into the patient. 
Figure 4. Application of CRISPR in the treatment of cardiovascular diseases. The somatic 
cells extracted from the patient are induced to IPS by the reprogramming process, then the 
genetic modification with CRISPR is performed on them. The differentiation process is then 
instituted on the modified cells and eventually transmitted to the patient 
Figure 5. Application of Genomic Editing for iPS( Cells). The creation of normal cells and 
targeted mutations cells using CRISPR. 
Figure 6. Evaluation of the effectiveness of gRNA to correct various types of DMD mutations in 
iPSC cells using exon skipping in the form of myoediting. 
Figure 7. Schematic to demonstrate the various ways to inhibit ANGPLT3 function. These 
include: a) Inhibiting transcripts using Antisense Oligonucleotide b) blocking antibodies c) 
CRISPR genomic editing with the aim of eliminating functional mutations, ultimately 
reducing levels of lipids. 
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Table 1. Advantages and disadvantages of the CRISPR / Cas9 system (19, 50-51). 
 
Advantages Disadvantages 
1. Site-specific gene targeting 
2. Effective, permanent mutations 
3. Screening DNA noncoding regions 
4. Can induce insertions or deletions 
5. At gene loci or chromosomally 
6. Heritable mutations 
7. Generation of mutant lines 
8. Can target multiple genes at once 
9. Fast and easy-to-use technique  
10. Short sgRNAs 
1. Requirement of a PAM sequence in the target DNA and a “seed” region in the crRNA  
2. Binding efficiency impacted by chromatin accessibility 
3. Varying degrees of specificity 
4. Toxicity 
5. Off-target effects 
6. Certain sites cannot be mutagenized 
7. Mosaicism 
8. Multiple alleles 
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